Cargando…
Omalizumab for Severe Asthma: Beyond Allergic Asthma
Different subsets of asthma patients may be recognized according to the exposure trigger and the frequency and severity of clinical signs and symptoms. Regarding the exposure trigger, generally asthma can be classified as allergic (or atopic) and nonallergic (or nonatopic). Allergic and nonallergic...
Autores principales: | Loureiro, C. C., Amaral, L., Ferreira, J. A., Lima, R., Pardal, C., Fernandes, I., Semedo, L., Arrobas, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166383/ https://www.ncbi.nlm.nih.gov/pubmed/30310816 http://dx.doi.org/10.1155/2018/3254094 |
Ejemplares similares
-
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022) -
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017) -
Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022) -
Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008) -
Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)